|
IGF2R expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62703184258817E-12 |
| Normal-vs-Stage2 |
1.018850E-03 |
| Normal-vs-Stage3 |
3.4202000120942E-09 |
| Normal-vs-Stage4 |
1.73140000114813E-08 |
| Stage1-vs-Stage2 |
1.019610E-01 |
| Stage1-vs-Stage3 |
7.296600E-01 |
| Stage1-vs-Stage4 |
2.560600E-01 |
| Stage2-vs-Stage3 |
1.861980E-01 |
| Stage2-vs-Stage4 |
1.911980E-02 |
| Stage3-vs-Stage4 |
1.909570E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.02719999999879E-05 |
| Normal-vs-Asian |
4.20199999995319E-06 |
| Caucasian-vs-AfricanAmerican |
1.836830E-01 |
| Caucasian-vs-Asian |
8.383000E-01 |
| AfricanAmerican-vs-Asian |
3.244800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.93659998937568E-09 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
3.366400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.17443857259059E-14 |
| Normal-vs-Age(41-60Yrs) |
1.96287430753728E-12 |
| Normal-vs-Age(61-80Yrs) |
1.4525000002763E-07 |
| Normal-vs-Age(81-100Yrs) |
2.471900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.761700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.470200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.133800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.534000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.570000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.719400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.230800E-01 |
| Classical-VS-Follicular |
1.46019996094537E-09 |
| Classical-VS-Other |
6.314500E-02 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
9.95400000000091E-05 |
| Tall-VS-Other |
2.505900E-02 |
| Tall-VS-Normal |
6.97579999986431E-07 |
| Follicular-VS-Other |
8.961200E-01 |
| Follicular-VS-Normal |
2.580100E-02 |
| Other-VS-Normal |
2.654000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.18349996469647E-09 |
| Normal-vs-N1 |
3.53669999997308E-06 |
| N0-vs-N1 |
1.197420E-01 |
|
|
